July 19, 2024 Biodexa Pharmaceuticals PLC Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals…
COLORADO SPRINGS, Colo., July 18, 2024 /PRNewswire/ -- Neurointerventional surgeons from across the globe will gather at the Society of…
K2 Laboratory recently announced that its two investigational drugs, Brain Rehabilitation oral solution and Telomerase Inhibitor oral solution, have successfully…
North Bergen, New Jersey--(Newsfile Corp. - July 18, 2024) - Apollo Biowellness, Inc. (OTC Pink: KOAN) (the "Company") is pleased…
‘Breaking Barriers’ Coalition Formed to Address Opioid Use Disorder in the USA Nexalin CEO Mark White Participates in Inaugural Meeting…
As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women’s Hospital and Baptist Hospital of…
Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC Development Master Plan is designed to…
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar…
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic…
MELBOURNE, Australia, July 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update…